Celltrion Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Hyong-Gi Kim

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	10.4yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.4yrs

Jüngste Management Updates

Recent updates

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Geschäftsführer

Hyong-Gi Kim (59 yo)

10.4yrs

Amtszeit

Mr. Hyong-Gi Kim serves as Chief Executive Officer at Celltrion, Inc. Mr. Kim served as Vice President of Celltrion Pharm Inc. He served as Head of Strategy and Planning Team, Daewoo Motor Company. He serv...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Hyong-Gi Kim	CEO & Internal Director	10.4yrs	keine Daten	0.10% ₩ 42.0b
Woo-Sung Kee	CEO & Internal Director	10.4yrs	keine Daten	0.090% ₩ 37.7b
Jin-seok Seo	Co-CEO & Inside Co-Chairman of the Board	3.4yrs	keine Daten	keine Daten
Jung-Jin Seo	Inside Co-Chairman of the Board	12.4yrs	keine Daten	4.17% ₩ 1.8t
Soon-Woo Lee	Independent Director	2.4yrs	keine Daten	keine Daten
Byoung Jeon	Independent Outside Director	10.4yrs	keine Daten	keine Daten
Jong Lee	Independent Outside Director	9.7yrs	keine Daten	keine Daten
Byung-oh Kwon	Director	no data	keine Daten	0.00091% ₩ 383.0m
Keun-young Kim	Independent Director	2.4yrs	keine Daten	keine Daten
Young-hyeh Ko	Independent Director	2.4yrs	keine Daten	keine Daten
Jae-sik Lee	Independent Director	2.4yrs	keine Daten	keine Daten
Dae-hyun Yoo	Independent Director	2.4yrs	keine Daten	keine Daten

3.4yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: A068270Die Vorstandsmitglieder gelten als erfahren (3.2 Jahre durchschnittliche Amtszeit).

Celltrion Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Recent updates

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Celltrion, Inc. (KOSE:A068270) completed the acquisition of portfolio of select non-core otc and prescription pharmaceutical products exclusively in Asia Pacific from Takeda Pharmaceutical Company Limited (TSE:4502).

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

New 90-day high: ₩330,000

Celltrion Presents Efficacy and Safety Data for Potential Covid-19 Treatment Candidate Ct-P59 in Patients with Mild Symptoms

New 90-day low: ₩245,500

New 90-day low: ₩278,500

Price target raised to ₩284,353

Geschäftsführer

Amtszeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter